Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

The report also notes a challenge Vertex will face: convincing insurers to cover its drug, which costs much more than opioids. The wholesale price is $15.50 per 50 mg tablet taken twice daily.

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write ...

Ahead of the drug’s approval, Stuart Arbuckle, Vertex’s chief operations officer ... the list of prescription drugs that Optum Rx covers is still evaluating the clinical data underpinning ...

Google launched Vertex AI way back in 2021 as a platform ... for other publications such as the Financial Times. Ingrid covers mobile, digital media, advertising and the spaces where these intersect.

Great. Well thanks very much, everyone, for joining us for our next session with Vertex. My name is Dave Risinger. For those of you who don't know me, I cover Diversified Biopharmaceuticals.

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...